Angiolab Company Description

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases.

Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis.

Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity.

In addition, the company provides ob-X for visceral fat reduction; and specific function and health functional food.

Further, it offers AL201-AB, which is in the pre-clinical stage for the treatment of cancer, ocular diseases, etc. The company was founded in 1999 and is headquartered in Daejeon, South Korea.

Angiolab, Inc.

Country	South Korea
Founded	1999
Industry	Biological Products, Except Diagnostic Substances
CEO	Min-Young Kim

Contact Details

Address: Hanshin S Mecca Suite 159 Daejeon South Korea
Phone	82 4 2867 5785
Website	angiolab.co.kr

Stock Details

Ticker Symbol	251280
Exchange	Korea New Exchange
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Min-Young Kim	Chief Executive Officer